MedPath

Fluoride ion F-18

Generic Name
Fluoride ion F-18
Brand Names
Sodium Fluoride F-18
Drug Type
Small Molecule
Chemical Formula
F
CAS Number
67862-54-8
Unique Ingredient Identifier
4M4WE5N2GE
Background

Sodium Fluoride F 18 Injection is a positron emitting radiopharmaceutical, no-carrier added. It contains radioactive fluoride F 18 that is used for diagnostic purposes in conjunction with positron emission tomography (PET) imaging and is administered by intravenous injection. Its primary indication is for bone imaging. Increased deposition around joints can occur in arthritis and following trauma and increased deposition in bone has been noted around fracture sites, in osteomyelitis, fibrous dysplasia, spondylitis tuberculosa, and Paget's disease. No adverse reactions have been reported.

Indication

18F is used as a bone imaging agent to define areas of altered osteogenic activity. It has been indicated for back pain and otherwise unexplained bone pain, child abuse, abnormal radiographic or laboratory findings, osteomyelitis, trauma, inflammatory and degenerative arthritis, avascular necrosis. Osteonecrosis of the mandible, condylar hyperplasia, and metabolic bone disease are also among the indications for fluoride imaging.

Associated Conditions
Altered osteogenesis, Altered osteogenic activity

Comparing an Investigational Scan (F-18 NaF PET/CT) to Standard of Care Imaging (F-18 FDG PET/CT) for Evaluating Vascular Complications in Patients Receiving Radiation Therapy for Head and Neck Cancer

Early Phase 1
Recruiting
Conditions
Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Head and Neck Squamous Cell Carcinoma
Hypopharyngeal Squamous Cell Carcinoma
Laryngeal Squamous Cell Carcinoma
Oropharyngeal Squamous Cell Carcinoma
Stage III Hypopharyngeal Carcinoma AJCC v8
Stage III Laryngeal Cancer AJCC v8
Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Interventions
Procedure: Computed Tomography
Other: Fludeoxyglucose F-18
Radiation: Intensity-Modulated Radiation Therapy
Procedure: Intensity-Modulated Proton Therapy
Procedure: Positron Emission Tomography
First Posted Date
2025-04-07
Last Posted Date
2025-04-07
Lead Sponsor
Emory University
Target Recruit Count
20
Registration Number
NCT06914999
Locations
πŸ‡ΊπŸ‡Έ

Emory University Hospital Midtown, Atlanta, Georgia, United States

Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer

Phase 2
Recruiting
Conditions
Sporadic Papillary Renal Cell Carcinoma
Stage IV Renal Cell Cancer AJCC v8
Hereditary Leiomyomatosis and Renal Cell Carcinoma
Renal Cell Carcinoma
Papillary Renal Cell Carcinoma
Stage III Renal Cell Cancer AJCC v8
Interventions
Procedure: Biopsy Procedure
Procedure: Biospecimen Collection
Procedure: Bone Scan
Procedure: Computed Tomography
Procedure: Computed Tomography with Contrast
Procedure: Magnetic Resonance Imaging
Procedure: Positron Emission Tomography
First Posted Date
2021-07-29
Last Posted Date
2025-04-17
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
65
Registration Number
NCT04981509
Locations
πŸ‡ΊπŸ‡Έ

Emory University Hospital Midtown, Atlanta, Georgia, United States

πŸ‡ΊπŸ‡Έ

Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States

πŸ‡ΊπŸ‡Έ

Emory Saint Joseph's Hospital, Atlanta, Georgia, United States

and more 9 locations
Β© Copyright 2025. All Rights Reserved by MedPath